COMM domain containing 4 pseudogene 2Genealiases: []
Q-omics provides the consensus-scored COMMD4P2 profile across patient tissues and cancer cell-line models. COMMD4P2 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, COMMD4P2 is differentially expressed in 2, with the highest sampling consensus in LIHC. Additionally, COMMD4P2 RNA expression shows 4,993 significant protein co-abundance associations, with the highest sampling consensus in OV. Together, these results highlight KIRC, LIHC, and OV as cancer lineages where COMMD4P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COMMD4P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COMMD4P2 survival associations across molecular data types. COMMD4P2 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COMMD4P2 RNA expression–survival associations across cancer types. High COMMD4P2 expression shows unfavorable associations in KIRC, READ, ACC, THCA, THYM and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for COMMD4P2 RNA expression.
This table summarizes COMMD4P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for COMMD4P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COMMD4P2 shows lower tumor expression in LIHC and CHOL. The LIHC box plot shows higher COMMD4P2 RNA expression in normal versus tumor tissue (log2 FC = −0.067, t-test p = .004).
This table shows molecular features associated with COMMD4P2 in patient tissues and cancer cell lines. In patient samples, COMMD4P2 shows the broadest associations at the RNA and protein expression levels, with OV recurring as the lineage with the largest associated feature set.
